Evidence map›Paper›PMID 37222840›Full record

ReviewCurrent microbiology2023

Interaction Between SARS-CoV-2 and Pathogenic Bacteria.

Parvindokht Fazel, Hamid Sedighian, Elham Behzadi, Reza Kachuei, Abbas Ali Imani Fooladi

Open access · bronzeAbstract readReview
In one paragraph

Review in Current microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Pathogen growth and virulence dynamics drive the host evolution against coinfections.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Article
  5. A Fraction ofInternational journal of molecular sciences · 2025
    Article
  6. SARS-CoV-2 andFrontiers in cellular and infection microbiology · 2025
    Observational
  7. Article
  8. Article
  9. Article
  10. The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection.Frontiers in cellular and infection microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Parvindokht Fazel *Department of Microbiology, Fars Science and Research Branch, Islamic Azad University, Eqlid, Fars, Iran.
Hamid Sedighian *Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Vanak Sq, Mollasadra St, P.O. Box 19395-5487, Tehran, Iran.
Elham BehzadiAcademy of Medical Sciences of the I.R. of Iran, Tehran, Iran.
Reza KachueiMolecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Abbas Ali Imani FooladiApplied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Vanak Sq, Mollasadra St, P.O. Box 19395-5487, Tehran, Iran. imanifouladi.a@gmail.com.ORCID http://orcid.org/0000-0001-7339-8257
Baqiyatallah University of Medical Sciences · IRIranian Academy of Medical Sciences · IRIslamic Azad University, Science and Research Branch · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The novel human coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which results in the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. Therefore, many studies are performed on the causes and prevalence of this disease and the possible co-occurrence of the infection with other viral and bacterial pathogens is investigated. Respiratory infections predispose patients to co-infections and these lead to increased disease severity and mortality. Numerous types of antibiotics have been employed for the prevention and treatment of bacterial co-infection and secondary bacterial infections in patients with a SARS-CoV-2 infection. Although antibiotics do not directly affect SARS-CoV-2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co-infection rather than virus itself. Therefore, bacterial co-infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID-19. In this review, we will summarize the bacterial co-infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID-19.

Indexed as

CoinfectionCOVID-19Respiratory Tract InfectionsAnti-Bacterial AgentsBacteriaHumansSARS-CoV-2Anti-Bacterial Agents

Identifiers

PMID37222840
PMCPMC10206355
OpenAlexW4377940620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.